1049706-72-0

Basic information

• Product Name: 3-Bromo-4-methyl-5-nitropyridin-2-ol
• Synonyms: 3-Bromo-4-methyl-5-nitropyridin-2-ol;3-BroMo-4-Methyl-5-nitro-2-pyridinone;3-BroMo-4-Methyl-5-nitropyridin-2(1H)-one;2(1H)-Pyridinone,3-bromo-4-methyl-5-nitro-;3-bromo-4-methyl-5-nitro-1H-pyridin-2-one;3-Bromo-4-methyl-5-nitropyridin-2(1H)
• CAS NO: 1049706-72-0
• Molecular Formula: C₆H₅BrN₂O₃
• Molecular Weight: 233.0195
• Mol File: 1049706-72-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 382.506 °C at 760 mmHg
• Flash Point: 185.133 °C
• Appearance: /
• Density: 1.858 g/cm³
• Storage Temp.: 2-8°C
• PKA: 6.61±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-4-methyl-5-nitropyridin-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-4-methyl-5-nitropyridin-2-ol(1049706-72-0)
• EPA Substance Registry System: 3-Bromo-4-methyl-5-nitropyridin-2-ol(1049706-72-0)

Safety Data

• Hazardous Substances Data: 1049706-72-0(Hazardous Substances Data)

Usage

Preparation

3-bromo-4-methyl-5-nitropyridin-2-ol synthesis: 4-Methyl-5-nitropyridin-2-ol (104.5 g, 0.68 mol) was suspended in AcOH (1000 mL) and bromine (208 mL, 6 eq) was added dropwise in 1.5 h. The mixture was stirred for 5 min, the poured into icewater (2000 mL) and stirred for 1 h. The resulting suspension was filtered and the residue was washed with water (3*100 mL), dried in vacuo and then stripped with toluene (2*500 mL) and CH3CN (500 mL). This afforded 3-bromo-4-methyl-5-nitropyridin-2-ol as a yellow solid (143.8 g, 91%).

Upstream product

• 21901-41-7 2-hydroxy-4-methyl-5-nitropyridine 
• 21901-41-7 4-methyl-5-nitropyridin-2(1H)-one 

Downstream Products

• 1150618-07-7 C₈H₇BrN₂O₄ 
• 1049706-74-2 3-bromo-2-(4-chloro-3-trifluoromethylphenoxy)-4-methyl-5-nitropyridine 

Relevant articles and documents

Discovery of [1,2,4]Triazolo[1,5- a]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse Agonists

The retinoic acid receptor-related orphan nuclear receptor γt (RORγt), a promising therapeutic target, is a major transcription factor of genes related to psoriasis pathogenesis such as interleukin (IL)-17A, IL-22, and IL-23R. On the basis of the X-ray cocrystal structure of RORγt with 1a, an analogue of the known piperazine RORγt inverse agonist 1, triazolopyridine derivatives of 1 were designed and synthesized, and analogue 3a was found to be a potent RORγt inverse agonist. Structure-activity relationship studies on 3a, focusing on the treatment of its metabolically unstable cyclopentyl ring and the central piperazine core, led to a novel analogue, namely, 6-methyl-N-(7-methyl-8-(((2S,4S)-2-methyl-1-(4,4,4-trifluoro-3-(trifluoromethyl)butanoyl)piperidin-4-yl)oxy)[1,2,4]triazolo[1,5-a]pyridin-6-yl)nicotinamide (5a), which exhibited strong RORγt inhibitory activity and a favorable pharmacokinetic profile. Moreover, the in vitro and in vivo evaluation of 5a in a human whole-blood assay and a mouse IL-18/23-induced cytokine expression model revealed its robust and dose-dependent inhibitory effect on IL-17A production.

PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS

The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.

NOVEL MICROBIOCIDES

Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.